These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 20642559)

  • 1. Palonosetron induced anaphylaxis in an adult female.
    Gupta YK; Shanmugam SP; Padhy BM; Goyal A
    Br J Clin Pharmacol; 2010 Jul; 70(1):149-50. PubMed ID: 20642559
    [No Abstract]   [Full Text] [Related]  

  • 2. Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy.
    Musso M; Scalone R; Bonanno V; Crescimanno A; Polizzi V; Porretto F; Bianchini C; Perrone T
    Support Care Cancer; 2009 Feb; 17(2):205-9. PubMed ID: 18839220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palonosetron: in the prevention of nausea and vomiting.
    Yang LP; Scott LJ
    Drugs; 2009 Nov; 69(16):2257-78. PubMed ID: 19852528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study.
    Rozzi A; Nardoni C; Corona M; Restuccia MR; Fabi A; Bria E; Minniti G; Lanzetta G
    Support Care Cancer; 2011 May; 19(5):697-701. PubMed ID: 20467757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Palonosetron-induced migraine-type headache.
    Jain A
    Can J Anaesth; 2011 Feb; 58(2):230-1. PubMed ID: 21132477
    [No Abstract]   [Full Text] [Related]  

  • 6. Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children.
    Sepúlveda-Vildósola AC; Betanzos-Cabrera Y; Lastiri GG; Rivera-Márquez H; Villasis-Keever MA; Del Angel VW; Díaz FC; López-Aguilar E
    Arch Med Res; 2008 Aug; 39(6):601-6. PubMed ID: 18662592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Rubenstein EB
    Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting in elderly patients.
    Aapro MS; Macciocchi A; Gridelli C
    J Support Oncol; 2005; 3(5):369-74. PubMed ID: 16218261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta-analysis.
    Jin Y; Sun W; Gu D; Yang J; Xu Z; Chen J
    Eur J Cancer Care (Engl); 2013 Jan; 22(1):41-50. PubMed ID: 22519361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palonosetron: more than just another option?
    Di Maio M; Perrone F
    Lancet Oncol; 2009 Feb; 10(2):100-1. PubMed ID: 19185827
    [No Abstract]   [Full Text] [Related]  

  • 11. Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia.
    Mattiuzzi GN; Cortes JE; Blamble DA; Bekele BN; Xiao L; Cabanillas M; Borthakur G; O'Brien S; Kantarjian H
    Cancer; 2010 Dec; 116(24):5659-66. PubMed ID: 21218459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palonosetron. RS 25259, RS 25259 197.
    Drugs R D; 1999 Oct; 2(4):251-2. PubMed ID: 10659403
    [No Abstract]   [Full Text] [Related]  

  • 13. Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist.
    Navari RM
    Future Oncol; 2006 Oct; 2(5):591-602. PubMed ID: 17026451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Palonosetron in combination with 1-day versus 3-day dexamethasone to prevent nausea and vomiting in patients receiving paclitaxel and carboplatin.
    Furukawa N; Kanayama S; Tanase Y; Ito F
    Support Care Cancer; 2015 Nov; 23(11):3317-22. PubMed ID: 25947257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Possible anaphylaxis to palonoestron.
    Pietkiewicz JM
    J Oncol Pharm Pract; 2012 Jun; 18(2):296-8. PubMed ID: 21859745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant.
    Grote T; Hajdenberg J; Cartmell A; Ferguson S; Ginkel A; Charu V
    J Support Oncol; 2006 Sep; 4(8):403-8. PubMed ID: 17004515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is a dexamethasone-sparing strategy capable of preventing acute and delayed emesis caused by combined doxorubicin and paclitaxel for breast cancer? Analysis of a phase II trial.
    Damian S; Celio L; De Benedictis E; Mariani P; Agustoni F; Ricchini F; De Braud F
    Oncology; 2013; 84(6):371-7. PubMed ID: 23711719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Medical treatment of chemotherapy-induced nausea and vomiting].
    Herrstedt J
    Ugeskr Laeger; 2007 Feb; 169(9):799-805. PubMed ID: 17355844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response.
    Massa E; Astara G; Madeddu C; Dessì M; Loi C; Lepori S; Mantovani G
    Crit Rev Oncol Hematol; 2009 Apr; 70(1):83-91. PubMed ID: 18723369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of palonosetron in postoperative nausea and vomiting (PONV)-a meta-analysis.
    Singh PM; Borle A; Gouda D; Makkar JK; Arora MK; Trikha A; Sinha A; Goudra B
    J Clin Anesth; 2016 Nov; 34():459-82. PubMed ID: 27687434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.